GlassScriptPhysician profile
Jon Luigi Haddad
NPI 1891762787
$19,419.63
in general payments reported to CMS, 2019-2025
33 companies · $3,342 in 2025
The $3,342 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,040 · 2020: $1,887 · 2021: $1,573 · 2022: $1,986 · 2023: $5,987 · 2024: $1,604 · 2025: $3,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,673 · Travel and Lodging: $3,361 · Long Term Medical Supply Or Device Loan: $1,880 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,672.79 |
| Travel and Lodging | $3,360.91 |
| Long Term Medical Supply Or Device Loan | $1,880.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $4,800.61 | 2023-2024 | Indigo System |
| Abbott Laboratories | $3,211.84 | 2019-2025 | Jeti All In One Non-Sterile Kit, Ultreon, Jeti |
| Angiodynamics, INC. | $2,499.79 | 2019-2025 | Venacure 1470 Pro, Venacure 1470 Pro |
| Medtronic Vascular, INC. | $1,426.80 | 2019-2020 | |
| Amarin Pharma, INC. | $1,277.07 | 2019-2022 | |
| Medtronic, INC. | $1,182.19 | 2021-2025 | Symplicity G3, Closurefast, Venaseal |
| Amgen INC. | $626.10 | 2020-2025 | Repatha, Repatha |
| Abiomed | $573.37 | 2019-2024 | Impella |
| Boston Scientific Corporation | $532.16 | 2020-2025 | General - Balloon Catheters |
| Novartis Pharmaceuticals Corporation | $516.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $344.87 | 2020-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.91 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $263.97 | 2022-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $219.30 | 2022-2025 | Verquvo |
| Pfizer INC. | $217.70 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $152.78 | 2021 | |
| Teleflex LLC | $150.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $147.04 | 2019-2024 | Xarelto |
| Biotronik INC. | $144.24 | 2019-2021 | |
| Philips North America LLC | $140.20 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $133.27 | 2023-2024 | Inpefa |
| Intact Vascular, INC. | $114.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $99.78 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.40 | 2022-2025 | |
| Bard Peripheral Vascular, INC. | $76.05 | 2020-2021 | |
| Itamar Medical INC | $43.04 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.02 | 2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $23.30 | 2023 | Praluent, Evkeeza |
| Esperion Therapeutics, INC. | $19.03 | 2020 | |
| Scpharmaceuticals INC. | $19.01 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $17.76 | 2023 | Opsumit, Uptravi |
| Tactile Systems Technology INC | $13.72 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,200,004.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.